To determine if the same dependency is evident in additional KRAS-mutant, CRC cell lines, we evaluated this therapeutic approach in two isogenic human cell line systems (LIM1215, and SW48) that comprise a series of KRAS mutant alleles, similar to the mouse cells. This evidence concerns the gene KRAS and colorectal carcinoma.